1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxylic acid - CAS 1221343-14-1
Catalog: |
BB061008 |
Product Name: |
1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxylic acid |
CAS: |
1221343-14-1 |
Synonyms: |
1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxylic acid; 1-hydroxy-1,3-dihydro-2,1-benzoxaborole-6-carboxylic acid; 1-hydroxy-3H-2,1-benzoxaborole-6-carboxylic acid; 1,3-dihydro-1-hydroxy- |
IUPAC Name: | 1-hydroxy-3H-2,1-benzoxaborole-6-carboxylic acid |
Description: | 1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxylic acid |
Molecular Weight: | 177.95 |
Molecular Formula: | C8H7BO4 |
Canonical SMILES: | B1(C2=C(CO1)C=CC(=C2)C(=O)O)O |
InChI: | InChI=1S/C8H7BO4/c10-8(11)5-1-2-6-4-13-9(12)7(6)3-5/h1-3,12H,4H2,(H,10,11) |
InChI Key: | VXDGEAYKTHEYPI-UHFFFAOYSA-N |
Melting Point: | 209 - 212°C |
Solubility: | Acetone (Slightly, Heated), DMSO (Slightly), Methanol (Slightly) |
Appearance: | White to Off-White Solid |
Storage: | Hygroscopic, -20°C Freezer, Under inert atmosphere |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
WO-2021202802-A1 | Conjugates for selective responsiveness to vicinal diols | 20200331 |
WO-2021055849-A1 | Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents | 20190919 |
WO-2020201041-A2 | Glucose sensitive insulin derivatives | 20190329 |
AU-2020255195-A1 | Glucose sensitive insulin derivatives | 20190329 |
CN-113646329-A | Glucose-sensitive insulin derivatives | 20190329 |
EP-3946363-A2 | Glucose sensitive insulin derivatives | 20190329 |
IL-285664-D0 | Glucose-sensitive insulin derivatives | 20190329 |
KR-20210148143-A | Glucose Sensitive Insulin Derivatives | 20190329 |
WO-2020114499-A1 | Tyrosine kinase inhibitors, compositions and methods there of | 20181207 |
TW-202033526-A | Compounds used as tyrosine kinase inhibitors, pharmaceutical compositions containing them, and uses thereof | 20181207 |
Complexity: | 220 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 178.0437389 |
Formal Charge: | 0 |
Heavy Atom Count: | 13 |
Hydrogen Bond Acceptor Count: | 4 |
Hydrogen Bond Donor Count: | 2 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 178.0437389 |
Rotatable Bond Count: | 1 |
Topological Polar Surface Area: | 66.8Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS